"Exceptional response rates in patients" in #CLL clinical trial, which looks at the safety of using a combination of #venetoclax and #ibrutinib, and then treatment efficiency. youtu.be/VUWtHwgdJLYIn this video, Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, presents the first interim analysis of the HOVON-141 study (... ... See MoreSee Less
Our #CLL community has told us that they need more Emotional Support. So on 19 October 2018 we're delighted to be hosting an Evening of Support with a talk by Louise O'Driscoll, Clinical Psychologist. It's our first event outside Dublin and is on in the Mullingar Park Hotel in Co. Westmeath from 6.30 - 9pm. It's FREE to attend but Registration is required. See our website for more details and the link to Register. ow.ly/RCYA30lmFjV... See MoreSee Less
"Patients with #CLL have a sizable 600% higher risk of melanoma, the most dangerous form of #skincancer... Although a higher risk of melanoma had been known, a full analysis of detection rates and treatments among CLL patients has never been reported before" ow.ly/uZM830ln8N3... See MoreSee Less
Obinutuzumab/Chlorambucil as Frontline CLL Option CLL11 study randomized 781 patients "with the purpose of improving treatment of unfit elderly #CLL patients by the use of immunochemotherapy & to compare... rituximab with obinutuzumab head to head” ow.ly/rj6h30ljs9L... See MoreSee Less
According to long-term follow-up data from the phase III CLL11 study, treatment with obinutuzumab combined with chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities. These findings....
Ibrutinib/Rituximab Emerges as New Standard in Waldenstrom Macroglobulinemia Phase III iNNOVATE trial results indicate combination reduced risk for disease progression or death by 80% vs rituximab alone in Waldenström patients. ow.ly/kOTs30ljrBc via OncLive.com ... See MoreSee Less
"...Every doctor I know has more than one story about a patient who died because they chose to try to alkalinize their blood or gambled on intravenous vitamins instead of getting cancer care.." | via The New York Times Dr Robert O'Connor ow.ly/IrtC30ljrJa... See MoreSee Less
Preclinical data points that Novel CD19/CD3 bispecific antibody used when patients have been treated with #ibrutinib may transform exhausted T cells into effective mediators of long-lasting disease control in #CLL | via Blood Journal ow.ly/Sywu30lgSZR... See MoreSee Less
Generating effective immune responses in patients with chronic lymphocytic leukemia (CLL) without the concomitant toxicity of complications of graft-versus-host disease (GVHD) seen with allogeneic stem cell transplant (SCT) remains an elusive goal. In this issue of Blood , [Robinson et al]
An inspiration to CLL Ireland - an incredible team: "...founded in 1998, the Multiple Myeloma Research Foundation has helped accelerate ten myeloma drugs to market, from Takeda’s Velcade to Johnson & Johnson’s Darzalex, by speeding up clinical trials...." ow.ly/5C5a30ldhD5... See MoreSee Less
In 1996, Kathy Giusti, then a 37-year-old pharmaceutical sales exec with a new baby, was told she had blood cancer, multiple myeloma, and three years to live. She refused to act like her life was over.
Bone marrow stem cells are the factories that produce new T-cells. But rather than simply genetically modifying T-cells, Ribas is modifying the bone marrow stem cells that make them. In other words, he's modifying the car factory, not just the car... ow.ly/9e9r30lcvBC... See MoreSee Less